Thomas L. Andresen

Thomas L. Andresen has an extensive work experience spanning over two decades. Thomas L. began their career in 2001 as the Head of Research and Development at LiPlasome Pharma A/S. In 2006, they moved to Risø National Laboratory as a Senior Scientist & Group Leader. In 2008, they joined Technical University of Denmark (DTU) as a Professor, Head of Institute of Health Technology, Head of DTU Nanotech, Head of Center for Nanomedicine and Theranostics, and Co-Director of DTU Nanotech. In 2012, they co-founded Nanovi A/S and held the positions of Co-founder, Board Member, Chair of the Board, and Chief Scientific Officer. In 2015, they co-founded Repertoire Immune Medicines / Torque Therapeutics and held the roles of Co-founder and Chief Scientific Officer. In 2016, they co-founded MonTa Biosciences and acted as a Co-Founder and Board Member. In 2017, they became a Scientific Advisor at Lipoid - Phospholipid Research Center. Finally, in 2021, they became the Chief Executive Officer of T-Cypher Bio.

Thomas L. Andresen obtained a Master of Science (MSc) in Chemistry from DTU - Technical University of Denmark between 1996 and 2001. Thomas L. then continued their studies at the same university, earning a Doctor of Philosophy (PhD) in Drug Delivery in 2005.